Asian Phytoceuticals Public Company (APCO) Fair Value & Analysis
Consumer Defensive · TH · Market cap 1.6B THB
Fair value as of: Jun 24, 2026
Analysis
Asian Phytoceuticals Public Company (APCO) currently trades at 2.54 THB, while our model-based Fair Value estimate is 1.42 THB — implying the stock looks roughly 44.1% overvalued today. We read business quality at 94/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Asian Phytoceuticals Public Company Limited engages in the research and development, manufacture, and distribution of healthcare and natural extracts-based beauty products in Thailand. The company offers cream and lotion products in bottles and tubes for massage to tighten the skin and reduce the desired area, and facial lotion products; and products for reverse aging, anti-aging, and longevity. It is also involved in the research on mangosteen under the project name Operation BIM. It also exports its products. The company was formerly known as Natural Cosmetics Research Co., Ltd. and changed its name to Asian Phytoceuticals Public Company Limited in July 2005. Asian Phytoceuticals Public Company Limited was founded in 1988 and is headquartered in Lamphun, Thailand.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Asian Phytoceuticals Public Company (APCO) undervalued?
What is the fair value of APCO?
What is the quality score of APCO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.